This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dan's Most Recent Article

Buying Bluebird's Blockbuster Potential at a Discount

07/17/14 - 10:33 AM EDT

It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.

read more >

Other Articles by Dan

Free Reports

Why I'm More Confident in Sarepta Than Ever Before

11/04/13 - 10:06 AM EST

Biotech trader Dan Rosenblum believes the recent selloff in Sarepta is a tremendous buying opportunity.

read more >
Sarepta: Staying Long and Strong

04/25/13 - 09:25 AM EDT

Contributor Dan Rosenblum believes Sarepta's upside potential far outweighs the risk in the stock.

read more >
Sarepta Is Undervalued Even Without Eteplirsen Accelerated Approval

03/05/13 - 10:39 AM EST

The exon-skipping drug technology is worth a lot more than just eteplirsen alone.

read more >
Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013

12/20/12 - 07:30 AM EST

Insiders at Auxilium and Aveo appear to be betting on turnarounds for both stocks in the next year.

read more >
Still Bullish on BioMarin, Lexicon Pharma

11/07/12 - 11:28 AM EST

TheStreet contributor Dan Rosenblum explains why he still likes BioMarin and Lexicon Pharma.

read more >
Sunshine Heart: A Promising Treatment for Heart Failure Patients

11/05/12 - 08:00 AM EST

Sunshine's C-Pulse is a heart-assist device for patients who fall between the cracks of current therapy.

read more >
Lexicon Pharma: Blockbuster Potential From A Diabetes Drug

10/16/12 - 06:10 AM EDT

Lexicons mid-stage diabetes drug blocks the reabsorption of blood sugar.

read more >
Biomarin: Four Clinical Trial Events to Watch Before Year End

09/25/12 - 07:03 AM EDT

TheStreet contributor Dan Rosenblum explains why Biomarin is a very busy biotech.

read more >
Nanosphere: A Low-Risk, High-Growth Diagnostic Stock

09/18/12 - 07:13 AM EDT

A hospital-based sepsis test is the launching pad for Nanosphere.

read more >
Page 1 of 2
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs